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Summary 
During the inflammatory response, endothelial cells (EC) transiently upregulate a set of genes 
encoding, among others, cell adhesion molecules and chemotactic cytokines that together me- 
diate the interaction of  the endothelium with cells of the immune system. Gene upregulation is 
mediated predominantly at the transcriptional level and in many cases involves the transcription 
factor nuclear factor (NF) KB. We have tested the concept of inhibiting the inflammatory re- 
sponse by overexpression of a specific inhibitor of NF-KB, IKBot. A  recombinant adenovirus 
expressing Ir,  B~x was constructed (rAd.IKBe  0 and used to infect EC of human and porcine ori- 
gin. Ectopic expression of IgJ3a resulted in marked, and in some cases complete, reduction of 
the expression of several markers of  EC activation, including vascular cell adhesion molecule 1, 
interleukins 1, 6, 8, and tissue  factor. Overexpressed IKBot inhibited NF-K_B specifically since 
(a) in electrophoretic mobility shift assay, NF-r,B but not AP-1 binding activity was inhibited, 
and (b) von Willebrand factor and prostacyclin secretion that occur independently of NF-r,B, 
remained unaffected. Functional studies of leukocyte adhesion demonstrated strong inhibition 
of ilL-60 adhesion to IKBot-expressing EC. These findings suggest that NF-KB could be an at- 
tractive target for therapeutic intervention in a variety of inflammatory diseases, including xe- 
nograft rejection. 
egulation  of gene  expression  at  the  transcriptional 
evel is governed by the presence of distinct transcrip- 
tion factors binding to specific sites in the promoter region, 
and in some cases other regions, of  the respective gene. Prom- 
inent among transcriptional activators for inducible genes 
in  general is  the  transcription factor nuclear factor (NFp 
r,_B. NF-KB is involved in the transient expression of many 
different genes in a variety of cell types and in response to 
diverse physiological and pathological stimuli.  Examples in- 
clude  the  expression  of IL-2,  TCR,  IgK  light  chain, 
MHC-1,  [3-IFN,  G-CSF,  GM-CSF,  proenkephalin,  an- 
giotensinogen,  and  acute  phase  genes,  the  majority  of 
which are involved in immune- and host-defense functions 
(for reviews, see references 1-4). In endothelial cells  (EC), 
genes that are dependent on NF-r,B include, among oth- 
1Abbreviations used in  this paper: EC,  endothelial cells; EMSA, electro- 
phoretic mobility shift assay; HUVEC, human umbilical vein EC; moi, 
multiplicity of  infection; NF, nuclear  factor; NLS, nuclear  localization  se- 
quence; PAEC, porcine aortic EC; rAd.Ir,  Bet, recombinant adenovirus 
expressing IKBct; TLCK, L-l-chlor-3-(4-tosylamido)-7-amino-2-hep- 
tanon-hydrochlorid;  VCAM-1, vascular cell adhesion molecule 1; vWF, 
von Willebrand factor. 
ers, IL-I, -6, and -8, monocyte chemoattractant protein 1, 
E-selectin,  intercellular  adhesion  molecule  1  (ICAM-1), 
vascular cell adhesion molecule 1 (VCAM-1), inducible nitric 
oxide synthase and tissue factor. Deletion mutagenesis and 
reporter gene  analysis  have  demonstrated  that  NF-KB  is 
necessary, although usually not alone sufficient, for the ex- 
pression of these genes. 
NF-KB represents a family of proteins comprising differ- 
ent members, including Rel (c-Rel;  5),  RelA (p65; 6-8), 
RelB  (9,  10),  NF-KB1  (p50;  11-13),  and NF-r,  B2  (p52; 
14-17). They form homo- or heterodimers with different 
affinities  for variants of a decameric consensus binding site 
(GGGRNNYYCC, where R indicates A or G, Y indicates 
C or T, and N indicates any base). The prototype NF-r,B is 
composed of the p50/p65  subunits,  however, in EC it is 
primarily the p65/c-Rel heterodimer that has been impli- 
cated in regulatory functions. Several genes relevant for EC 
contain an atypical NF-KB binding site with the sequence 
HGGRNNYYCC  (where H  indicates A,  C,  or T),  sug- 
gesting a certain degree of cell type specificity of the other- 
wise ubiquitous NF-KB family (18). 
Regulation of  NF-r,B occurs through complex formation 
of the heterodimer with a cytoplasmic inhibitor, IKBo~ (19- 
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the cytoplasm by masking its nuclear localization sequence 
(23,  24).  Upon  appropriate  stimulation,  e.g.,  by  IL-lm 
TNF-m  or LPS, IKBoL is phosphorylated on two serine res- 
idues,  $32  and $36  (25,  26).  This phosphorylation renders 
It~Bo~ susceptible to  proteolytic degradation via  the  ubiq- 
uitin-proteasome pathway (27, 28), resulting in release and 
nuclear translocation of NF-KB. Resynthesis of IKBcx oc- 
curs  within  60  min  through  transcriptional activation by 
NF-KB p65 and c-lKel (29-33). 
In addition to retaining NF-KB in the cytoplasm, a sec- 
ond function has been demonstrated for IKBcx: it can pre- 
vent in vitro DNA  binding of NF-KB, namely of the p65 
and  c-Rel subunits  (19,  34).  Taking advantage of this at- 
tribute, we have constructed a recombinant adenovirus that 
expresses IKBoL (rAd.IKBo~) fused to a nuclear localization se- 
quence  (NLS). Targeting of the ectopically expressed IKBo~ 
to the nucleus should prevent its degradation by the cellular 
(cytoplasmic) degradation machinery and  allow inhibition 
of NF-KB binding to  its DNA  target sequence(s).  As de- 
scribed here, infection of EC with rAd.IKBcr results in suc- 
cessful inhibition of inflammatory cytokine-induced gene 
expression,  procoagulant activity,  and  leukocyte  adhesion 
to EC in vitro. 
Materials  and Methods 
EC Culture.  Enzymatic  isolation  and  culture  of EC  from 
porcine  aorta  was  done  as  described  (35).  Porcine  aortic  EC 
(PAEC) were grown on gelatine-coated cell culture flasks (Nunc, 
Roskilde,  Denmark)  in  complete  DMEM  supplemented  with 
10% FCS and glutamine. Human  umbilical vein EC  (HUVEC) 
were purchased from Technoclone (Vienna, Austria) and grown 
in medium 199  supplemented with 20%  bovine calf serum, EC 
growth factor, and heparin. For stimulation, 500 U/ml human re- 
combinant IL-lti, 200  U/ml human recombinant TNF-ct (both 
from  Genzyme  Corp.,  Cambridge,  /viA),  500  ng/ml  bacterial 
LPS,  or  3  U/ml  human  thrombin  (Sigma  Chemical  Co.,  St. 
Louis, MO) was used. 
Construction of Recombinant Adenovirus.  Construction of recom- 
binant adenovirus was done as described (36).  The first ATG of 
the porcine IKBot cDNA (22) was replaced by a BamHI restric- 
tion site using PCR. A double-stranded oligonucleotide (NLS-1; 
5'-CTAGAGTCGACATGCCCAAGAAGAAGAGGAAGGT- 
GGGCGGCG-3') encoding an initiator methionine followed by 
the SV40 large TAg NLS and three glycine residues as a flexible 
spacer was ligated into the newly generated BamHI site. The con- 
struct was sequenced to exclude possible errors generated during 
the amplification procedure, ligated into the vector pACCMV- 
pLpASR.+ (36),  and cotransfected together with pJM17,  a plas- 
mid containing the adenoviral genome with a deletion in the E1 
region (37) into 293  cells (Fig. 1 A). Clones obtained after sub- 
cloning on 293 cells were tested for IKBlx expression by Western 
blotting using an anti-MAD-3 antibody (Santa Cruz Biotechnol- 
ogy, Santa Cruz,  CA) at a dilution of 1:1,500.  Purification of a 
large batch of the recombinant adenovirus was done by two con- 
secutive cesium chloride centrifugations, as described (38). 
Infection of EC.  Postconfluent PAEC were washed once with 
complete PBS and incubated at a multiplicity of infection (moi) 
of 1,000  with rAd.IKBoL or control adenovirus (DL-312;  39)  in 
PBS. After 30 min at 37~  the adenovirus was washed off and 
fresh growth medium added. Cells were maintained for 3 d more 
until assayed. HUVEC were treated identically, except that a 10- 
fold lower amount of adenovirus was used (moi of 100). 
RNA Isolation and Northern Blotting.  RNA was extracted from 
PAEC, fractionated on formaldehyde/agarose gels, transferred to 
Hybond N  membranes (Amersham Corp., Arlington Heights, IL) 
and  hybridized to  random-primed  cDNA  probes  as  described 
(40).  Two  oligonucleotides, one complementary to NLS-1  (see 
above) and one complementary to position 92-118 (22) in the 5' 
untranslated region of porcine Iv,  BoL (5UTR;  5'-ATGAGGGC- 
TTGGGCGCTGCTCCCTAGGT-3')  were  used  as probes  to 
distinguish between endogenous and adenovirus-expressed IKBo~. 
Equivalent loading and transfer of RNA was confirmed by ethid- 
ium bromide staining of the gel and of the membrane after transfer. 
lmmunostaining.  Paraformaldehyde-fixed, NP-40 permeabilized 
cells were stained for IKBc~ using an anti-MAD-3 antibody at a 
dilution of 1:1,000 and a peroxidase-conjugated donkey anti-rab- 
bit second antibody (Amersham Corp.). Detection was performed 
using a  metal-enhanced diaminobenzidine substrate kit  (Pierce 
Chemical  Co.,  Rockford,  IL)  according to  the  manufacturer's 
protocol. 
Western Blotting.  Cells were lysed in Laemmli buffer and ana- 
lyzed by SDS-PAGE on  12.5% Minigels (Mini-Protean II; Bio- 
Rad Laboratories, Richmond, CA). For separation of the phos- 
phorylated and nonphosphorylated forms of IKB~x, samples were 
run  on  30-cm  gels  (10%).  IKBc~ was  detected using the  anti- 
MAD-3 antibody at a dilution of 1:1,500  and peroxidase-conju- 
gated donkey anti-rabbit second antibody followed by enhanced 
chemiluminescence (ECL) detection (Amersham Corp.). 
Nuclear Extracts and Electrophoretic Mobility  Shift Assay.  Nuclear 
proteins were extracted from PAEC, either infected with control 
virus or rAd.IKB~x, stimulated with 500 ng/ml TNF-a for 1 h or 
from nonstimulated cells, as described (41). The double-swanded oli- 
gonucleotides BS-2 representing a NF-v,B binding site from the 
porcine  IKBa  promoter  (5'-AATTCGGCTTGGAAATTC- 
CCCGAGCG-3'; 22), and the oligonucleotide TFAP-1 containing 
the tandem AP-1 site from the tissue factor promoter (5'-AAT- 
TGGGTTGAATCACGGGTGAATCAGCCCTTGCAGG-3';  42) 
were labeled by tilting in the EcolKI overhangs with Klenow en- 
zyme in the presence of radioactive nucleoside triphosphates and 
0.2 ng (100,000  cpm) used per lane in electrophoretic mobility 
shift assay (EMSA). The resulting complexes were separated on 
5% polyacrylamide gels. 
Cell ELISA.  HUVEC were grown in 96-well microtiter plates 
and cell ELISA performed essentially as described (43).  Briefly, 
cells  were  fixed with  glutaraldehyde and  blocked overnight  in 
PBS/5% BSA. Expression of VCAM-I  was determined using a 
monoclonal anti-VCAM-1 antibody at a  1:500  dilution (BBA5; 
British Biotechnology Ltd., Cowley, United Kingdom) and peroxi- 
d0se-coupled goat anti-mouse second antibody (Amersham  Corp.), 
followed by 0-nitrophenylene-diamine detection. Equal numbers 
of cells in  the  assay  were  determined by staining with  sulfor- 
hodamine B (Sigma Chemical Co.). 
Determination of Procoagulant Activity.  PAEC were stimulated for 
6  h  with  500  ng/ml LPS,  transferred to Eppendorf tubes,  col- 
lected by centrifugation, and resuspended in clotting buffer (12 
mM Na-acetate, 7 mM Na-barbital, 130 mM NaCI, pH, 7.4).  A 
100-~1  cell suspension was  combined with  100  I.~1 pig plasma 
(Sigma Chemical Co.)  and 100  ILl of 20 mM CaC12, and incu- 
bated at 37~  Time until clot formation was recorded and trans- 
formed into thromboplastin units using a standard curve. 
Determination of von Willebrand Factor Secretion.  HUVEC  grown 
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min. Supernatants were harvested and assayed for von Willebrand 
factor (vWF) using the Imubind vWF sandwich ELISA (Ameri- 
can Diagnostica Inc.,  Greenwich, CT).  Toxicity was controlled 
by assaying lactate dehydrogenase release (CytoTox96, Promega 
Corp., Madison, WI). 
Cell Adhesion Assay.  HUVEC  grown  in  24-well  microtiter 
plates were infected with  rAd.IKBa or control virus. 3  d  later, 
cells were stimulated with 500 U/ml IL-lc~ (Genzyme Corp.) for 
4 h or left unstimulated. HL-60 cells were labeled with CMFDA 
(5-chloromethylfluorescein  diacetate;  Molecular  Probes,  Inc., 
Eugene, OIL) at a concentration of 5 IxM for 20 min at 37~  as 
described by the manufacturer.  Labeled HL-60  cells  (106) were 
added to the HUVEC cultures in a total volume of 0.4 ml and in- 
cubated for 30 min at 37~  After two washes with PBS deficient, 
adhered HL-60 cells were quantitated by measuring the fluores- 
cence using 490- (excitation) and 520-nm (emission) filters. 
Determination of Prostacydin.  Prostacyclin (PGI2) was  determined 
by measuring the concentration of its hydrolysis product 6-keto- 
prostaglandin FI,~  by enzymeimmunoassay according to the man- 
ufacturer's protocol (Amersham Corp.). 
Figure  1.  Construction  and analysis of recombinant  adenovirus. (A) 
Schematic representation. (B) Kinetics of adenovirus-mediated IKBot  ex- 
pression. PAEC were infected with the rAd.IKBc~  and, after the indicated 
periods of time, analyzed  by SDS-PAGE (on minigels) and Western blot- 
thing using an anti-IKBct  antibody. In the last  lane, cells were treated with 
TNF-c~ for 1 h at day 3 after infection. Numbers on the right indicate 
molecular weight (kD). (C) Endogenous 1KBot is degraded and resynthe- 
sized in noninfected EC after stimulation with TNF-ct. Cells were ana- 
lyzed as in B with the anti-lr,  Bot antibody after the indicated periods of 
time. (D) IKBct-expressing  cells  were treated with the phosphatase inhibi- 
tor okadaic acid (OA), a protease inhibitor (TLCK), or with LPS for 45 
min and analyzed by high resolution SDS-PAGE and Western blotting. 
(IKBot*) Position of the phosphorylated form of Ir.Bct. Exposure times 
using ECL detection were 30 s in B and D and 10 rain in C. 
Results 
Construction and Characterization of a rAd.IKBc~.  Cotrans- 
fection of IKBot, cloned into the adenovirus transfer vector 
pACCMVpLpASR+,  together  with  the  plasmid  pJM17 
into  293  cells (Fig.  1  A)  resulted in  the  generation  of re- 
combinant adenovirus. After subcloning of the virus pool, 
individual clones were obtained and infected 293 cells were 
tested  by  Western  blotting  for  IKB0t  expression.  All  15 
clones tested expressed an immunoreactive protein of the 
expected size oflKBet. One clone (clone 15) was expanded 
further and used in the subsequent experiments. 
After infection of PAEC with the recombinant adenovi- 
rus, increasing expression of Ir,  Bot was observed up to day 3, 
with no further increase at day 4,  as determined by West- 
ern blotting (Fig.  1  B).  The  amounts  expressed were  esti- 
mated to be about 50 times higher as compared to the en- 
dogenous  protein  (data  not  shown).  Stimulation  of the 
infected cells at day 3  with LPS for 1 h  did not detectably 
decrease  IKl3et levels.  In  contrast,  in  noninfected  EC  the 
endogenous  protein was rapidly degraded followed by re- 
synthesis (Fig. 1  C), in accordance with published observa- 
tions (44). To determine whether addition of the NLS affects 
the  ability  of  Ir,  Bot  to  be  phosphorylated,  rAd.IKBet- 
infected cells were treated at day 3 after infection with LPS 
or with  the  phosphatase  inhibitor  okadaic  acid,  and  ana- 
lyzed by high resolution SDS-PAGE and Western blotting 
to resolve the phosphorylated and nonphosphorylated forms 
of IKBct. Treatment with okadaic acid resulted in the con- 
version  of ,'-~50%  of IKBet  into  the  phosphorylated form 
within  45  min,  whereas  LPS  stimulation  did not  lead  to 
generation of detectable amounts  of phosphorylated IKBot 
(Fig. 1 D). These results indicate that overexpressed, NLS- 
tagged IKBo~ can still be phosphorylated, but only by strong 
nonphysiological stimuli  (see Discussion).  Treatment  with 
the protease inhibitor L-l-chlor-3-(4-tosylamido)-7-amino- 
2-heptanon-hydrochlorid (TLCK)  alone in the  absence of 
additional stimuli also leads to IKBot phosphorylation, pos- 
sibly due to activation of the EC by the alkylating proper- 
ties of TLCK. 
To  achieve  expression  of IKBct  in  90-100%  of EC,  a 
1015  Wrighton et al. Figure  2.  Immunoperoxidase  staining of  HUVEC  infected  with 
rAd.lKB~t. 3 d after infection, cells were stained with an anti-bd3ot anti- 
body followed by immunoperoxidase detection.  (A and 13) rAd.IKBot- 
infected; (C and/9) control virus infected; (A and C) without phase con- 
trast; (B and/9) with phase contrast. 
moi of 100  had to be used for HUVEC,  as determined by 
immunoperoxidase staining (Fig. 2).  In contrast,  a  moi  of 
1,000 was needed to obtain the same percentage of PAEC 
staining positive for IK13o~, indicating a  significantly lower 
infectivity of the (human)  adenovirus towards porcine cells 
(not shown).  However,  the localization of Iv,  Bot appeared 
to  be  heterogeneous:  although  Iv,  Bo~  was  detected in  the 
nucleus,  most  cells  also  expressed  the  protein  to  varying 
amounts  in  the  cytoplasm. Since the  SV40  TAg NLS  has 
been  successfully transferred to  a  number  of heterologous 
proteins in  the  past,  the partial nuclear transport of NLS- 
IKBot might be due to inefficient recognition of the NLS, 
possibly because ofsteric hindrance. 
Northern  blot  analysis  showed  high  levels  of  IKt3Ot 
mRNA  in rAd.Icd30t-infected, but only small amounts cor- 
responding  to  the  endogenous  gene  in  control  virus-in- 
fected PAEC  (Fig. 3  A). To  distinguish whether increased 
IKBot mRNA  expression is of endogenous  or viral origin, 
hybridization was performed with an oligonucleotide spe- 
cific for a  sequence  (NLS) present only in the adenovirus- 
expressed but not in the endogenous bd3ot. A  specific band 
was detected only in rAd.IKBcl-infected, but not in nonin- 
fected or control virus-infected cells (Fig. 3  B). In turn,  an 
oligonucleotide directed against the 5'-untranslated region 
of IKBot (a region that is not present in the rAd.IKBIx ex- 
pression construct) recognized only the endogenous Icd3ot. 
Consistent  with  previous  findings  demonstrating  the  re- 
quirement  of NF-cd3  for  IKBot  expression  (22),  endoge- 
nous IKBot was downregulated in rAd.bd3ot-infected cells, 
whereas it was upregnlated in PAEC after stimulation with 
LPS (Fig. 3  C). 
Inhibition of  DNA Binding of  NF-KB.  The consequences 
of adenovirus-mediated overexpression of I K/3Ot on NF-KB 
are shown  in EMSA.  Nuclear extracts from either nonin- 
fected,  nonstimulated  or  stimulated  PAEC,  from  control 
virus-infected/stimulated  and  from  rAd.IKBa-infected/ 
Figure  3.  Northern  blot analysis of rAd.lKBa-infected cells. PAEC 
were infected with either the rAd.IKB~x  or a control adenovirus and le~ 
unstimulated or stimulated with LPS as indicated above each lane. Total 
RNA was isolated and probed for (A) VCAM-1,  IL-1, IL-6, IL-8, and 
IKBa expression as indicated. (13) I~13c~ expressed from the recombinant 
adenovirus was detected by hybridization with an oligonudeotide recog- 
nizing a sequence in the expression construct. (C) Endogenous IKBot  was 
detected by hybridization with an oligonucleotide recognizing a sequence 
present in the  5'-untranslated  region of bd3~x that had been  removed 
from the expression construct. Equal loading and transfer of KNAs was 
controlled by ethidium bromide staining of the gel and of the membrane 
after transfer, and by hybridization with a GAPDH probe. 
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fected, as well as control virus-infected cells showed strong 
inducible activity of NF-KB, no detectable binding of the 
transcription  factor  was  observed  in  rAd.IKB0t-infected 
cells,  with NF-KB levels even below the basal  amounts of 
noninfected, nonstimulated cells. The inhibitory effect was 
specific for NF-~B,  since binding of AP-l-like factors to 
their respective site remained unaffected. 
Inhibition of Gene Expression and Leukocyte Adhesion.  Since 
several genes that are characteristic for the inflammatory re- 
sponse in EC contain functional NF-KB binding sites in their 
promoter regions, we have analyzed the levels of some of 
these genes by Northern blotting in nonstimulated or stim- 
ulated,  either  noninfected,  rAd.IId3ot-  or  control  virus- 
infected EC. VCAM-1, IL-lot, IL-6, and IL-8 were induc- 
ible by LPS in noninfected and control virus-infected cells, 
but showed between 90 and 98% reduction of their steady- 
state mRNA levels in rAd.IKBct-infected cells  (Fig.  3 A). 
In some cases (IL-1 and IL-6), induction by the control virus 
was  observed, indicating some  effect of adenovirus infec- 
tion  itself on  the  EC  (45).  Levels  of glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) mR.NA were not af- 
fected by IKBot expression (Fig. 3 A). 
We also determined the expression of VCAM-1  by cell 
ELISA. The inhibitory effect oflK.Bot on VCAM-1 mRNA 
was reflected on the protein level, with reduction of  VCAM-1 
to basal levels (Fig. 5 A). Using a dotting assay as a measure- 
Figure 4.  EMSA. PAEC were infected with either rAd.l~d3et or a con- 
trol adenovirus and leK unstimulated or stimulated with LPS as indicated 
above each lane.  Nuclear extracts  were prepared and analyzed  by EMSA 
using double-stranded oligonucleotides containing either NF-KB or AP-1 
binding sites. 
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ment for tissue factor expression (42), virtually complete inhi- 
bition was observed (Fig. 5/3). In contrast, thrombin-induced 
levels ofvWF, a protein that is constitutively synthesized and 
its secretion regulated by release from intracellular storages, 
remained  unaffected  (Fig.  5  C).  In  addition,  the  LPS- 
induced  release  of prostacyclin was  similar  in  rAd.bd3ot- 
infected,  noninfected,  and  control  virus-infected  cells, 
demonstrating that LPS signaling pathways that are distinct 
from NF-~O3 activation are not affected. 
Binding  of human  promyelocytic HL-60  cells  to  acti- 
vated endothelium is mediated by several cell adhesion mole- 
cules on the EC surface, including VCAM-1  (46, 47). As 
expected,  repression  of VCAM-1  by  IK.Bot (and  also  of 
E-selectin and intercellular adhesion molecule 1; Wrighton, 
C.J.,  A. McShea,  tk.  de Martin,  and  F.H.  Buch,  unpub- 
lished  observations)  inhibited  adhesion  of HL-60 cells  to 
IL-l-stimulated HUVEC by 94% (Fig. 6). 
Discussion 
The current model of  NF-KB/bd3ot views this transcrip- 
tion factor and its inhibitor as an autoregulatory system for 
the control of transient gene expression. In quiescent, non- 
stimulated  cells,  complex formation  with  IKI3ot prevents 
nuclear  translocation of NF-KB.  After stimulation  of the 
cells, activation of NF-K.B directly causes the expression of 
IKBot, which in turn leads to the termination of NF-KB ac- 
tivity  and  NF-KB-dependent  gene  transcription  a  few 
hours after stimulation (29-33, 48). By premature expres- 
sion of IKBot, the balance between the two factors would 
therefore be shifted towards the "inactive" state. 
Antioxidants have been used in vitro to inhibit NF-KB 
in a variety of cell types, however, this class of compounds 
has  pleiotropic effects on various  other cellular functions 
(49). A more specific approach has utilized double-stranded 
phosphorothionate oligonucleotides as transcription factor 
"decoys," but high concentrations of the oligonucleotides 
were needed to achieve inhibition in the entire cell popu- 
lation (50).  Recently, inhibition of nuclear translocation of 
NF-~O31 was demonstrated after treatment of cells  with a 
cell-permeable peptide  containing the  NF-KB1  NLS  (51). 
In  transient  transfection  experiments  using  promoter- 
reporter genes,  cotransfection of Ird3ot resulted in  signifi- 
candy  reduced  expression  from  the  ELAM-1  as  well  as 
from an artificial  NF-KB--dependent promoter (44, 52). To 
assay the inhibitory effect of bd3ot on the expression of the 
endogenous genes and to allow biochemical analysis,  it is 
necessary to utilize a highly efficient transfection system. Ad- 
enovirus-mediated gene transfer meets this criterion: several 
groups have demonstrated that, using recombinant adeno- 
virus,  up  to  100%  of the  cells,  e.g.,  EC,  smooth  muscle 
cells, and hepatocytes, can be infected in vitro and in vivo 
(53-56).  Likewise,  using  a  recombinant  adenovirus,  we 
have been able to express IKBot in 90-100% of human and 
porcine EC. I~13ot was demonstrated to be expressed from 
the recombinant adenovirus, since: (a) control virus infec- 
tion did not lead to increased IKBot expression (Fig.  3 A); 0,8 
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Figure 5.  Determination ofVCAM-1, tissue factor, von WiUebrand factor, and prostacyclin in IKBcx  adenovirus-infected  cells. (A) HUVEC were in- 
fected with either the rAd.lKB~x or a control adenovirus and left unstimulated or stimulated as indicated. After 8 h, a cell ELISA  using an anti-VCAM-1 
antibody was performed. (B) PAEC were treated as above and procoagulant activity determined in a standard clotting assay. Clotting times were con- 
verted into tissue factor units using a standard curve. (C) HUVEC were treated as in A and vWF secretion determined by ELISA. (D) PAEC were treated 
as in (A), stimulated with LPS for 12 h, and prostacyclin measured by EIA. 
(b)  an  oligonucleotide  directed  against  the  NLS  of the 
IKB~  fusion  gene  detected  a  specific band  exclusively in 
lq.NA  from  rAd.IKB~-infected  cells  (Fig.  3  B);  and  (c) 
NLS-tagged  IKB<x shown  in  the  Western  blot  (Fig.  1  B) 
can be distinguished by its larger size from the endogenous 
gene  product  detected  after  long  exposure  (not  shown). 
We have noted that an approximately  10-fold higher virus 
titer is necessary to achieve similar amounts of porcine cells 
to become infected as compared to human EC, suggesting 
partial  species  incompatibilities  between  the  virus  and  its 
receptor on porcine cells. 
As shown by Western blot,  rAd.IKB~x-infected cells ex- 
pressed high levels oflKBe~, the amounts exceeding the endo- 
genous levels  by  approximately  50-fold.  Typically,  endo- 
genous  IKB0~  is  rapidly  degraded  within  minutes  after 
stimulation of cells with agents that lead to NF-KB activa- 
tion.  This  process  has  been  demonstrated  to  require  two 
distinct steps: first,  the phosphorylation oflKBo~ by a possibly 
very specific, yet unidentified kinase; and second, proteolytic 
degradation oflKBc~ via the ubiquitin-proteasome pathway 
(27,  28).  In  contrast,  upon  stimulation  of  rAd.IKBe~- 
infected cells,  the exogenous IKBo~ protein was not detect- 
ably degraded.  This could only partially be due to the nu- 
clear localization of the protein, since considerable amounts 
of  IKBcx were  found  in  the  cytoplasm.  To  determine 
whether overexpressed NLS-IKB~ cou]d still be phosphor- 
ylated,  we  treated  rAd.IKB~-infected  cells  with  LPS  and 
with  the  phosphatase  inhibitor  okadaic  acid,  and  deter- 
mined the amount of IKBo~ phosphorylation by high reso- 
lution  SDS-PAGE.  Treatment  with  okadaic acid, but not 
with LPS, resulted in conversion of significant amounts of 
IKBoL into  the phosphorylated form (Fig.  1 D).  The most 
likely  explanation  for  this  is  that,  although  adenovirus- 
expressed IKB~ can be phosphorylated, phosphorylation by 
LPS  is  limiting,  sufficient  for the  phosphorylation  of en- 
dogenous  levels  of IKBo~ but  not  for  the  approximately 
50-fold higher amounts generated by the recombinant ade- 
novirus.  These low levels of phospho-IKBoL were not de- 
tectable  because  of its  short half-life.  Attempts  to stabilize 
the phosphorylated IKBcx by preventing its  degradation us- 
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Figure  6.  Cell  adhesion  assay. HL-60  adhesion  to  noninfected, 
rAd.lKBa-  or  control  adenovirus-infected  HUVEC  was  determined. 
(Open bars) Unstimulated EC; (hatched bars) EC stimulated with 500 U/ml 
IL-1or for 4 h. Numbers of adhered HL-60 cells are  expressed as relative 
fluorescence after labeling  with the fluorescent dye CMFDA. 
ing the protease inhibitor TLCK were masked by the fact 
that  in  EC,  TLCK alone already lead to  significant  IKBoL 
phosphorylation. Alternatively, okadaic acid could activate 
a  kinase(s)  distinct  from  those  that  normally phosphory- 
late(s) IKBoL  under physiological conditions. Further exper- 
iments will be necessary to distinguish between these possi- 
bilities. 
Nuclear extracts from rAd.IKBot-infected, stimulated cells 
lacked  any  detectable  NF-KB  binding  activity,  even  less 
than  in  noninfected,  unstimulated  cells.  Concomitantly, 
LPS-induced levels of VCAM-1,  IL-1, and IL-8 mRNA, 
as well as VCAM-1 and procoagulant activity (expressed as 
units  per  milliliter tissue  factor), were  reduced by up  to 
98%.  The difference between an apparently complete lack 
of NF-KB activity and still partial mRNA expression indi- 
cates  that  either:  (a)  a  portion of noninfected cells  is  re- 
sponsible for the low overall mRNA expression that occurs 
independently in  each  cell,  whereas  in  EMSA,  the  high 
amounts of IKBa from the (pooled) nuclei of infected cells 
would also inhibit NF-KB from the portion ofnoninfected 
cells; or (b) a basal level of transcription can occur indepen- 
dently of NF-KB. In rAd.IKBot-infected cells,  tissue  factor 
expression measured as procoagulant activity was reduced 
to basal levels. However, in this assay, responses other than 
tissue  factor expression, e.g., downregulation of thrombo- 
modulin, might contribute to procoagulant activity. 
EC activation can be distinguished between two mecha- 
nistically  distinct  responses:  rapid  events  ("type I  activa- 
tion") such as translocation of P-selectin to the cell surface 
that occur independently of  protein synthesis, and late events 
(type II activation) that occur over hours and require mRNA 
and protein synthesis (57). vWF, a marker for type I activa- 
tion  in  EC,  is  released  from Weibel-Palade  bodies  after 
stimulation of EC independently of gene transcription.  In 
contrast to the inhibition of those genes mentioned above, 
IKBot overexpression did not affect the thrombin-induced 
vWF secretion, demonstrating that IKBot does not interfere 
with at least some aspects  of type I activation. In addition, 
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the LPS-stimulated secretion of prostacyclin remained un- 
affected, indicating that NF-KB-independent branches  of 
the LPS signaling pathway are not influenced by IKBoL. 
In some cases, however, we have noted that adenovirus 
infection per se has an effect on EC activation: IL-lot and 
IL-6 mlLNA levels were significantly enhanced in control 
virus-infected as  compared to  noninfected cells,  whereas 
the expression of other genes tested was not affected. In ad- 
dition, infection with the control adenovirus slightly stimu- 
lated vWF secretion (Wrighton, C.,  unpublished observa- 
tion). The molecular basis for this differential susceptibility 
of IL-lo~ and IL-6 towards adenovirus infection remains to 
be established. It is consistent with previous observations in 
the hterature  (45),  describing an inflammatory reaction in 
response to adenovirus. Moreover, enhanced serum levels 
of IL-6 have been attributed to the release of the preformed 
cytokine in  response to  adenovirus infection in a  clinical 
study with recombinant adenovirus expressing the cystic fi- 
brosis  transmembrane conductance regulator (58).  In con- 
trast,  our experiments suggest that enhanced IL-6 mRNA 
levels could contribute to increased IL-6 production after 
adenovirus infection. It is, therefore, conceivable that coin- 
fection with  rAd.IKBot  would  suppress  the  inflammatory 
reaction encountered with other recombinant adenoviruses 
used in ongoing gene therapy experiments. Studies to eval- 
uate this possibility are underway. 
The inhibition of cell adhesion molecule expression by 
IKBcx was reflected by inhibition of ilL-60 adhesion to EC 
in vitro. In vivo, under flow conditions, the interaction be- 
tween immune cells and the endothelium is more complex, 
involving an initial weak adhesion  (rolling)  that precedes 
firm adhesion and transmigration. Lymphocyte rolling has 
been demonstrated to involve members of the selectin fam- 
ily  (59),  whereas  sticking  and  emigration is  mediated by 
members of the immunoglobulin family on the EC surface 
interacting with integrins on the leukocytes (60).  In addi- 
tion, chemotactic and activating cytokines secreted by the 
EC  (activating  for  the  leukocyte  as  well  as  for  the  EC 
themselves) contribute to the inflammatory cascade.  How- 
ever, as demonstrated by the inhibition of expression oflL-8 
and other cytokines by IKBet, NF-KB appears to be a com- 
mon  mediator not  only for cell  adhesion  molecules, but 
also  for chemotactic and activating cytokines involved in 
the inflammatory reaction, suggesting that the strategy of 
inhibiting this transcription factor would also  function in 
vivo. Supportive of the concept of targeting NF-KB to pre- 
vent the inflammatory reaction are the recent findings that 
glucocorticoids,  the  most  potent  antiinflammatory  drugs 
available,  act at least in part by stimulating the expression of 
IKB0t, thereby downregulating NF-KB activity (61, 62). 
To  date,  it  is  not  clear  whether  adenovirus-mediated 
gene transfer as currently practiced will become a tool that 
can be used chnically on a routine basis. In xenotransplan- 
ration studies, where an inflammatory reaction appears to 
play a considerable role in the rejection process, perfusion 
of isolated  organs  with  rAd.IKBo~ before  transplantation 
could be feasible, though several aspects ofbiosafety, of du- 
ration of expression of the foreign gene and others need to be carefully evaluated. However, in the case of IKBot, ade- 
novirus  methodology offers  the  possibility to  extend  our 
studies to animal models of inflammation. Should these ex- 
periments confirm the in vitro data, other efforts to inhibit 
NF-KB,  possibly via  small  synthetic  molecules,  could  be 
developed into  a  promising strategy for the  clinical treat- 
ment of a wide range of inflammatory diseases. 
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